Patents Represented by Attorney, Agent or Law Firm Rae-Venter Law Group P.C.
-
Patent number: 6825332Abstract: Genes for familial hemeplegic migraine (FHM), episodic ataxia type-2 (EA-2), common forms of migraine, and other episodic neurological disorders, such as epilepsy, have been mapped to chromosome 19p13. A brain-specific P/Q type calcium channel subunit gene, covering 300 kb with 47 exons is provided. The exons and their surroundings reveal polymorphic variations and deleterious mutations that are linked to various types of cation channel dysfunctions causing episodic neurological disorders in man or animals.Type: GrantFiled: March 26, 1999Date of Patent: November 30, 2004Assignee: Rijksuniversiteit Tel LeidenInventors: Rune Robert Isak Erik Frants, Michel Dominique Ferrari, Gisela Marie Terwindt, Roel André Ophoff
-
Patent number: 6495155Abstract: An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.Type: GrantFiled: August 25, 2000Date of Patent: December 17, 2002Assignee: Southern Research InstituteInventors: Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell, Peter Markland
-
Patent number: 6475508Abstract: Described are compositions, methods, and articles of manufacture for the closure of retinal breaks with a non-toxic polymer. Transformation to a gel-like coat is achieved by photochemical reactivity, chemical reactivity, and by physicochemical response.Type: GrantFiled: September 7, 2000Date of Patent: November 5, 2002Assignees: Regents of the University of California, California Institute of TechnologyInventors: Daniel M. Schwartz, Jeffrey A. Hubbell, Alexander R. Irvine
-
Patent number: 6472415Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in indications associated with the androgen receptor, such as cell hyperplasia dependent on androgens, hirsutism, acne and androgenetic alopecia.Type: GrantFiled: February 11, 2000Date of Patent: October 29, 2002Assignee: Biophysica, Inc.Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglas, III, Brian Campion, Jason W. Brown
-
Patent number: 6465791Abstract: Diyne monomers are used as photochromic agents in devices or formulations. The devices and formulations may be applied to body parts for semi-pemanent attachment at various sites to allow for detection of levels of ultraviolet radiation. Clear films may be placed on eyeglass lenses to detect UV radiation occurring between the lens and the eye.Type: GrantFiled: March 30, 2000Date of Patent: October 15, 2002Assignee: Segan IndustriesInventors: Hans O. Ribi, David A. Frankel
-
Patent number: 6358699Abstract: ADMA is determined in a physiological sample by first removing interfering components: proteins by precipitation; and amines and citrulline, by means of a cation exchange column, followed by enzymatic hydrolysis of the ADMA to citrulline with DDAH. The citrulline is then determined spectrophotometrically.Type: GrantFiled: February 1, 2000Date of Patent: March 19, 2002Assignees: Cooke Pharma, Panorama Research, Inc.Inventors: Robert F. Balint, Mitchell Wayne Mutz, John P. Cooke
-
Patent number: 6350576Abstract: Nucleic acid sequence probes are provided for the detection of lesions associated with neoplastic cells. The sequences can be used for identifying the locus associated with the lesion, for determining cancer susceptibility of cells, as well as categorizing and characterizing tumor cells for prognosis and therapy.Type: GrantFiled: December 21, 1995Date of Patent: February 26, 2002Assignee: Cold Spring Harbor LaboratoryInventors: Michael Wigler, Nikolai Lisitsyn
-
Patent number: 6329570Abstract: Novel methods are provided whereby encoding sequences preferentially directing gene expression in ovary tissue, particularly in very early fruit development, are utilized to express genes encoding isopentenyl transferase in cotton ovule tissue. The methods permit the modification of the characteristics of boll set in cotton plants and provide a mechanism for altering fiber quality characteristics including fiber dimension and strength.Type: GrantFiled: February 28, 1995Date of Patent: December 11, 2001Assignee: Calgene, LLCInventor: Belinda Martineau
-
Patent number: 6319693Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.Type: GrantFiled: June 7, 1995Date of Patent: November 20, 2001Assignee: Leadd B.V.Inventors: Matheus H. M. Noteborn, Gerben F. de Boer
-
Patent number: 6306425Abstract: An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances.Type: GrantFiled: April 7, 2000Date of Patent: October 23, 2001Assignee: Southern Research InstituteInventors: Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell
-
Patent number: 6300493Abstract: Methods and compositions are provided for the modification of polysaccharide structures using polysaccharidase binding or catalytic domains either alone or in tandem to modify the structure of polysaccharides. These methods and compositions are exemplified by the use of cellulase binding and catalytic domains to polish cotton, and to alter dying characteristics, texture and porosity of cellulose fibers.Type: GrantFiled: October 13, 1998Date of Patent: October 9, 2001Assignee: University of British ColumbiaInventors: Neil R. Gilkes, Douglas G. Kilburn, Robert C. Miller, Jr., Anthony Warren
-
Patent number: 6288301Abstract: A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF&agr;, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF&agr; gene.Type: GrantFiled: July 30, 1998Date of Patent: September 11, 2001Assignees: Waratah Pharmaceuticals, Inc., The General Hospital CorporationInventors: Ronald V. Nardi, Stephen J. Brand
-
Patent number: 6277606Abstract: Methodology is provided for developing probes for identifying sequence differences between two related DNA populations, sets of DNA fragments or collections of restriction-endonuclease-cleaved DNA or cDNA. The method employs an initial stage to obtain a representation of both DNA populations, namely using the PCR to produce relatively short fragments, referred to as amplicons. Tester amplicons containing target DNA, sequences of interest, are ligated to adaptors and mixed with excess driver amplicons under melting and annealing conditions, followed by PCR amplification. The process may be repeated so as to greatly enrich the target DNA. Optionally, the target DNA may then be cloned and the DNA used as probes.Type: GrantFiled: March 2, 1999Date of Patent: August 21, 2001Assignee: Cold Spring Harbor LaboratoryInventors: Michael Wigler, Nikolai Lisitsyn
-
Patent number: 6238669Abstract: Circular double-stranded replication intermediates were identified in low-molecular-weight DNA of cells of the avian leukemia virus-induced lymphoblastoid cell line 1104-X-5 infected with chicken anemia virus (CAV). To characterize the genome of CAV, we cloned linearized CAV DNA into the vector pIC20H. Transfection of the circularized cloned insert into chicken cell lines caused a cytopathogenic effect, which was arrested when a chicken serum with neutralizing antibodies directed against CAV was added. The 2,319-bp cloned CAV DNA contained all the genetic information needed for the complete replication cycle of CAV. The CAV genome probably contains only one promoter region and only one poly(A) addition signal. Southern blot analysis using oligomers derived from the CAV DNA sequence showed that infected cells contained double- and single-stranded CAV DNAs, whereas purified virus contained only the minus strand.Type: GrantFiled: August 13, 1997Date of Patent: May 29, 2001Assignee: Leadd, bvInventors: Mathews H. M. Noteborn, Gerden F. De Boer
-
Patent number: 6222097Abstract: Novel DNA constructs are provided which may be used as molecular probes or inserted into a plant host to provide for modification of transcription of a DNA sequence of interest in ovary tissue, particularly in very early fruit development. The DNA constructs comprise a transcriptional initiation regulatory region associated with gene expression in ovary tissue from immediately prior to anthesis through flower senescence.Type: GrantFiled: December 3, 1997Date of Patent: April 24, 2001Assignee: Calgene, LLCInventors: Kevin E. McBride, David M. Stalker
-
Patent number: 6184249Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in the therapy of indications associated with the androgen receptor, such as, hirsutism, acne and androgenetic alopecia, and in the therapy and diagnosis of cell hyperplasia dependent on androgens.Type: GrantFiled: December 18, 1998Date of Patent: February 6, 2001Assignee: Biophysica, Inc.Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglass, III, Brian Campion, Jason W. Brown
-
Patent number: 6176962Abstract: Methods are provided for the fabrication of polymeric microchannel structures having enclosed microchannels of capillary dimension. The microchannel structures are constructed of a base plate and a cover, sealed together. Microchannel structures having walls of a plastic material are formed in a generally planar surface of at least the base plate. The cover has at least one generally planar surface, and the microchannel structures are enclosed by bonding the planar surfaces of the cover and the base plate together. In some embodiments the surfaces of the cover and base plate are both of plastic material, and are directly thermally bonded. In some embodiments a bonding material is applied to one of the surface prior to bringing the surfaces together. Suitable bonding materials are disclosed.Type: GrantFiled: June 18, 1997Date of Patent: January 23, 2001Assignee: Aclara Biosciences, Inc.Inventors: David S. Soane, Zoya M. Soane, Herbert H. Hooper, M. Goretty Alonso Amigo
-
Patent number: 6174700Abstract: A compound having a polysaccharide binding domain such as contained by a cellulose and essentially lacking in polysaccharidase activity is purified from other ingredients in a mixture using an affinity partition system. A mixture containing the compound is contacted with a system containing as a first phase an aqueous solution of oligosaccharide polymer such as cellulose and as a second phase a solution of a polymer such as a poly(ethylene glycol)-poly(propylene glycol) copolymer. The compound petitions into the first phase and binds to the oligosaccharide polymer, preferably with a Ka of 103 to 107, to form a complex. The complex is collected, and the compound is dissociated from the oligosaccharide polymer. The compound may be formed of a non-peptide chemical moiety or a peptide moiety linked to a polypeptide having the polysaccharide binding domain.Type: GrantFiled: July 24, 1995Date of Patent: January 16, 2001Assignee: University of British ColumbiaInventors: Charles A. Haynes, Peter Tomme, Douglas G. Kilburn
-
Patent number: 6162461Abstract: The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge.Type: GrantFiled: June 7, 1995Date of Patent: December 19, 2000Assignee: Leadd B.V.Inventors: Matheus Hubertus Maria Noteborn, Guus Koch
-
Patent number: RE37727Abstract: Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.Type: GrantFiled: January 20, 2000Date of Patent: June 4, 2002Assignee: Hind Health CareInventor: Harry W. Hind